Access to anti-retroviral drugs, female in Yemen

Yemen: Access to anti-retroviral drugs, female was 34.0% in 2024. ◆ Volatile

Latest (2024)
34.0%
Change on year
up 3.0%
World rank
132nd
of 141 countries
All-time high
34.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Yemen, 2000–2024

01020302000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 0 %2007: 2 %2008: 4 %2009: 5 %2010: 9 %2011: 11 %2012: 12 %2013: 14 %2014: 18 %2015: 19 %2016: 23 %2017: 25 %2018: 26 %2019: 28 %2020: 29 %2021: 29 %2022: 31 %2023: 33 %2024: 34 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Yemen stood at 34.0%. That is the highest value across all 25 years on record.

That represents a change of up 3.0% on the previous year and up 88.9% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Yemen peaked at 34.0% in 2024 and was at its lowest, 0.0%, in 2000.

Yemen ranks 132nd of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Yemen, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Yemen, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 0.0%
2007 2.0%
2008 4.0% +100.0%
2009 5.0% +25.0%
2010 9.0% +80.0%
2011 11.0% +22.2%
2012 12.0% +9.1%
2013 14.0% +16.7%
2014 18.0% +28.6%
2015 19.0% +5.6%
2016 23.0% +21.1%
2017 25.0% +8.7%
2018 26.0% +4.0%
2019 28.0% +7.7%
2020 29.0% +3.6%
2021 29.0% +0.0%
2022 31.0% +6.9%
2023 33.0% +6.5%
2024 34.0% +3.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 1.1% 0.0% 5.0% 10
2010s 18.5% 9.0% 28.0% 10
2020s 31.2% 29.0% 34.0% 5

Countries ranked near Yemen

  1. 129 Afghanistan 38.0% compare
  2. 130 Indonesia 36.0% compare
  3. 130 Mongolia 36.0% compare
  4. 133 Bangladesh 33.0% compare
  5. 133 Congo 33.0% compare
  6. 133 Tunisia 33.0% compare

See the full ranking of 160 places →

More gender data for Yemen

All data for Yemen →

Frequently asked questions

What is access to anti-retroviral drugs, female in Yemen?
Access to anti-retroviral drugs, female in Yemen was 34.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Yemen?
The highest recorded value was 34.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Yemen?
The lowest recorded value was 0.0% in 2000.
How does Yemen rank for access to anti-retroviral drugs, female?
Yemen ranks 132nd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Yemen?
Over the last ten years it is up 88.9%. The long-run trend across the full record is volatile.
Where does this Yemen data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Yemen. Statizoid, drawing on UNAIDS estimates. Retrieved 12 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/yemen-rep/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/yemen-rep/">Access to anti-retroviral drugs, female in Yemen</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.